BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Genetic Technologies Limited (GTG.AX) Announces New Record Growth In Number Of BREVAGen™ Tests Received For December Quarter


1/9/2014 9:43:51 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MELBOURNE, AUSTRALIA--(Marketwired - January 08, 2014) - Genetic Technologies Limited (NASDAQ: GENE) (ASX: GTG) today announced that a new record number of BREVAGen™ test samples were received during the quarter ended December 31, 2013. Total patient samples received during the quarter was 1,125, representing growth of more than 23% over the preceding September quarter and demonstrating a continuation of the significant increase trend in market traction.

"We are pleased to report another record quarter in samples received for our flagship breast cancer risk assessment test, BREVAGen," said Tom Howitt, acting CEO of Genetic Technologies. "Our continued growth has been achieved through just a modest increase in the number of sales representatives within key states as we achieved incremental licensure. We are particularly encouraged to see the increased growth rate during this December quarter, given the two major holiday periods, both of which have a seasonal impact on the numbers of tests ordered."

Launched in the first fiscal quarter of 2012, BREVAGen test sample receipts have demonstrated consistent growth, increasing every quarter to-date. The test is now available for sale in all 50 U.S. states.

About Genetic Technologies Limited
Genetic Technologies was an early pioneer in recognizing important new applications for "non-coding" DNA (Deoxyribonucleic Acid). The Company has since been granted patents in 24 countries around the world, securing intellectual property rights for particular uses of non-coding DNA in genetic analysis and gene mapping across all genes in all species. Its business strategy is the global commercialization of its patents through an active out-licensing program and the global expansion of its oncology and cancer management diagnostics portfolio. Genetic Technologies is an ASX and NASDAQ listed company with operations in the USA and Australia. For more information, please visit www.gtglabs.com.

Safe Harbor Statement
Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with Genetic Technologies' business can be found in its periodic filings with the SEC.


FOR FURTHER INFORMATION PLEASE CONTACT

Mr. Tom Howitt
Chief Executive Officer (Acting)
Genetic Technologies Limited
Phone: +61 3 8412 7000

Laura Forman (US)
Blueprint Life Science Group
+1 (415) 375 3340, Ext. 103



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES